Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2131 AL 2145

Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease

Herrmann N, Wang HJ, Song BX, Bawa KK, Lanctôt KL.

Expert Opin Drug Saf. 2022 Oct;21(10):1289-1301. doi: 10.1080/14740338.2022.2136162. Epub 2022 Oct 20.

Impact of Major Depressive Disorder on Comorbidities: A Systematic Literature Review

Arnaud AM, Brister TS, Duckworth K, Foxworth P, Fulwider T, Suthoff ED, Werneburg B, Aleksanderek I, Reinhart ML.

J Clin Psychiatry. 2022 Oct 19;83(6):21r14328. doi: 10.4088/JCP.21r14328.

Cognitive improvement effects of Tian Wang Bu Xin Dan (Cheonwangbosimdan) in patients with mild cognitive impairment: protocol for a randomized placebo-controlled pilot clinical trial

Kim JH, Cho MR, Yoo J, Park GC, Lee JS.

Ann Palliat Med. 2022 Oct;11(10):3320-3329. doi: 10.21037/apm-22-701. Epub 2022 Oct 11.

Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial

Schneider LS, Bennett DA, Farlow MR, Peskind ER, Raskind MA, Sano M, Stern Y, Haneline S, Welsh-Bohmer KA, O'Neil J, Walter R, Maresca S, Culp M, Alexander R, Saunders AM, Burns DK, Chiang C.

J Prev Alzheimers Dis. 2022;9(4):625-634. doi: 10.14283/jpad.2022.72.

Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial

Viña J, Escudero J, Baquero M, Cebrián M, Carbonell-Asíns JA, Muñoz JE, Satorres E, Meléndez JC, Ferrer-Rebolleda J, Cózar-Santiago MDP, Santabárbara-Gómez JM, Jové M, Pamplona R, Tarazona-Santabalbina FJ, Borrás C.

Alzheimers Res Ther. 2022 Nov 4;14(1):164. doi: 10.1186/s13195-022-01097-2.

The effects of synthetic glucocorticoid treatment for inflammatory disease on brain structure, function, and dementia outcomes: A systematic review

Shorey CL, Mulla RT, Mielke JG.

Brain Res. 2023 Jan 1;1798:148157. doi: 10.1016/j.brainres.2022.148157. Epub 2022 Nov 8.

Therapeutics for mitochondrial dysfunction-linked diseases in Down syndrome

Ganguly BB, Kadam NN.

Mitochondrion. 2023 Jan;68:25-43. doi: 10.1016/j.mito.2022.11.003. Epub 2022 Nov 9.

Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias

Perlett L, Smith EE.

Clin Geriatr Med. 2023 Feb;39(1):135-149. doi: 10.1016/j.cger.2022.07.008. Epub 2022 Oct 18.

Alzheimer's disease and related dementias is a risk factor for lower utilization of breast cancer screening and unstaged cancer diagnosis: Observational study from SEER-Medicare 2004-2016 data

Weng X, Shen C, Vasekar M, Boltz M, Joshi M, Van Scoy LJ, Wang L.

J Geriatr Oncol. 2023 Apr;14(3):101407. doi: 10.1016/j.jgo.2022.11.006. Epub 2022 Nov 26.

Effects of Kami Guibi-tang in patients with mild cognitive impairment: study protocol for a phase III, randomized, double-blind, and placebo-controlled trial

Shin HY, Yim TB, Heo HM, Jahng GH, Kwon S, Cho SY, Park SU, Jung WS, Moon SK, Ko CN, Park JM.

BMC Complement Med Ther. 2022 Dec 2;22(1):318. doi: 10.1186/s12906-022-03805-9.

Extra-Virgin Olive Oil Enhances the Blood-Brain Barrier Function in Mild Cognitive Impairment: A Randomized Controlled Trial

Kaddoumi A, Denney TS Jr, Deshpande G, Robinson JL, Beyers RJ, Redden DT, Praticò D, Kyriakides TC, Lu B, Kirby AN, Beck DT, Merner ND.

Nutrients. 2022 Dec 1;14(23):5102. doi: 10.3390/nu14235102.

Probiotic supplementation improved cognitive function in cognitively impaired and healthy older adults: a systematic review of recent trials

Handajani YS, Hengky A, Schröder-Butterfill E, Hogervorst E, Turana Y.

Neurol Sci. 2023 Apr;44(4):1163-1169. doi: 10.1007/s10072-022-06540-8. Epub 2022 Dec 19.

Omega-3 fatty acids and cognitive function

Welty FK.

Curr Opin Lipidol. 2023 Feb 1;34(1):12-21. doi: 10.1097/MOL.0000000000000862. Epub 2022 Nov 25.

An Insight into the Role of Artificial Intelligence in the Early Diagnosis of Alzheimer's Disease

Verma RK, Pandey M, Chawla P, Choudhury H, Mayuren J, Bhattamisra SK, Gorain B, Raja MAG, Amjad MW, Obaidur Rahman S.

CNS Neurol Disord Drug Targets. 2022;21(10):901-912. doi: 10.2174/1871527320666210512014505.

Circulatory GSK-3β: Blood-Based Biomarker and Therapeutic Target for Alzheimer's Disease

Kumari S, Singh A, Singh AK, Yadav Y, Bajpai S, Kumar P, Upadhyay AD, Shekhar S, Dwivedi S, Dey AB, Dey S.

J Alzheimers Dis. 2022;85(1):249-260. doi: 10.3233/JAD-215347.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias